{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-048850","form_type":"8-K","ticker":"OCUL","cik":"0001393434","company_name":"OCULAR THERAPEUTIX, INC","filed_at":"2024-04-18T23:59:59+00:00","discovered_at":"2026-05-14T18:03:18.209986+00:00","generated_at":"2026-06-03T18:35:29.196472+00:00","sec_items":["5.02","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Ocular Therapeutix appoints Pravin Dugel as CEO, Nadia Waheed as CMO; stock plan increased","bullets":["Pravin U. Dugel appointed President and CEO, effective April 14, 2024; he remains Executive Chairman.","Prior CEO Antony C. Mattessich resigned; severance includes 24 months base salary and 24-month equity acceleration.","Nadia Waheed appointed Chief Medical Officer effective May 20, 2024, replacing Rabia Gurses Ozden.","2019 Inducement Stock Incentive Plan amended to increase shares from 3,804,000 to 4,804,000."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-048850","json":"https://secwatch.observer/filing/0001104659-24-048850.json","markdown":"https://secwatch.observer/filing/0001104659-24-048850.md","text":"https://secwatch.observer/filing/0001104659-24-048850.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1393434/000110465924048850/0001104659-24-048850-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1393434/000110465924048850/tm2412141d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-03T18:35:29.196472+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"5f407e91a5","claim":"Pravin U. Dugel, M.D. was appointed as President and Chief Executive Officer at OCULAR THERAPEUTIX, INC.","evidence_excerpt":"On April 14, 2024 (the “Transition Date”), the board of directors of Ocular Therapeutix, Inc. (the “Company”) appointed Pravin U. Dugel, M.D., to serve as President and Chief Executive Officer of the Company.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1393434/000110465924048850/0001104659-24-048850-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"President and Chief Executive Officer"}],"fact_type":"executive_change"},{"claim_id":"a2919b5c9b","claim":"Antony C. Mattessich resigned as President and Chief Executive Officer at OCULAR THERAPEUTIX, INC.","evidence_excerpt":"On the Transition Date, Dr. Dugel succeeded Antony C. Mattessich as the Company’s President and Chief Executive Officer, and Mr. Mattessich resigned from the board of directors of the Company.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1393434/000110465924048850/0001104659-24-048850-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"President and Chief Executive Officer"}],"fact_type":"executive_change"},{"claim_id":"d9d50b7afc","claim":"Rabia Gurses Ozden, M.D. departed as Chief Medical Officer at OCULAR THERAPEUTIX, INC.","evidence_excerpt":"Effective upon the commencement of Dr. Waheed’s employment, Rabia Gurses Ozden, M.D., will cease to serve as the company’s Chief Medical Officer.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1393434/000110465924048850/0001104659-24-048850-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"ceased"},{"label":"Role","value":"Chief Medical Officer"}],"fact_type":"executive_change"},{"claim_id":"e1b1cf1a3f","claim":"Nadia Waheed, M.D. was appointed as Chief Medical Officer at OCULAR THERAPEUTIX, INC.","evidence_excerpt":"On April 16, 2024, the Company announced that Nadia Waheed, M.D., had been appointed to serve as Chief Medical Officer of the Company, effective upon the anticipated commencement of her employment with the Company on May 20, 2024.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1393434/000110465924048850/0001104659-24-048850-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Medical Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}